VaxInnate gains $40M in third round

VaxInnate, which is developing new flu vaccines, has raised $40 million in its third round of venture capital. The company is relying on its Toll-like receptor technology to develop a new generation of vaccines that are far more effective and less expensive to produce than today's vaccines. New Leaf Venture Partners led the round, joined by Canaan Partners. Existing investors HealthCare Ventures, Oxford Bioscience Partners, MedImmune Ventures, and CHL Medical Partners also participated in this round.

- see the release on the round

ALSO: Cytheris, a French biotech, has raised $30.7 million in its second round. The new round enables Cytheris to complete Phase II trials of its IL-7 program for HIV. The funds are also earmarked for the preclinical development of its new drug candidate selected from a NKT/Dendritic cell activators platform. Release

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.